Yahoo Finance23d
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
Basel, 22 January 2025 - Roche (SIX: RO, ROG ... with commercialisation under CE mark expected to follow shortly. “Rapid molecular point-of-care testing can revolutionise the clinical management ...
pharmaphorum4mon
Roche launches 'revolutionary' pathogen detection tech
The new test is compatible with Roche's cobas 5800, 6800, and 8800 molecular diagnostic analysers ... of SARS-CoV-2 assays on the cobas 6800/8800 systems since the end of the pandemic.
Hosted on MSN22d
Roche’s STI assay panels gain FDA 510(k) clearance and CLIA waiver
Roche Diagnostics CEO Matt Sause said: “Rapid molecular point-of-care testing ... CE mark certification for its updated cobas 6800/8800 systems 2.0, enhancing laboratory and testing capabilities.
pharmaphorum2d
Roche sticks with molecular glue, partnering Monte Rosa
Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...